ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko), reported that the results from the global multicenter Phase III MANEUVER study of its self-developed novel, oral, highly selective, and potent small molecule CSF-1R inhibitor, Beijiemai® (Pimitespib Hydrochloride Capsules, ABSK021), were officially published in the international medical journal The Lancet on March 5 (Western European Time). This publication represents a significant milestone for Abbisko, highlighting the quality of clinical research, data integrity, and international academic recognition for this innovative therapy.